Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma

NCT00327600 is registered in ClinicalTrials.gov with AmpliMed Corporation as lead sponsor.

NCT NCT00327600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00327600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Lead sponsor
AmpliMed Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2005
Completion date
December 31, 2007
Enrollment
68 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma